Document is current

Article History

Received: 23 September 2024

Accepted: 31 October 2024

First Online: 19 December 2024

Declarations

:

: Pauline Frank was an employee of Novartis Pharma AG during the period in which this survey was designed, conducted, and results interpreted. She was affiliated with Patient Co-Next GmbH at the time the manuscript was developed. Julie Laurent is a current employee for ELSECARE Inc. Lorraine Dallas participated in advisory boards (for AstraZeneca, Bayer, BMS, Janssen, Lily, MSD, and Novartis) in 2019 and 2020 and received expert consultant fee for her participation to the present study. Her department at Roy Castle Lung Cancer Foundation has been supported by unconditional grants (from AstraZeneca, MSD, Janssen, BMS and Takeda), as well as funding from the Global Lung Ambition Alliance. Pasquale Varriale was employed at ELSECARE Inc. at the time this survey was conducted, and at Merck Sharp & Dohme when the manuscript was developed. Andrew Ciupek’s organization received consulting fees from Novartis, Seagen, Gilead, Regeneron and Daiichi Sankyo, as well as honoraria for presentations from Glaxo Smith Kline.

: The questionnaire and survey conduct were approved by the Western Institutional Review Board Copernicus Group. Eligible respondents gave electronic informed consent prior to participation. The survey was conducted in accordance with the Declaration of Helsinki and all standards of Good Clinical Practice (GCP), as well as US-healthcare personal data protection law (HIPAA, Health Insurance Portability and Accountability Act), as well as European laws and regulations (GDPR, General Data Protection Regulation).